Clinical Trial Update: Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function [Phase 1]

View source ↗

Summary

Phase 1 trial of sorafenib in patients with metastatic or unresectable solid tumors, multiple myeloma, or non-Hodgkin lymphomas; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Multiple Myeloma
• Nodal Marginal Zone B-cell Lymphoma

Drugs mentioned

• Nexavar (sorafenib) (sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Status: COMPLETED